West Pharma (WST) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
West Announces Fourth-Quarter and Full-Year 2016 Results and Announces Quarterly Dividend
February 16, 2017 7:01 AM ESTEXTON, Pa., Feb. 16, 2017 /PRNewswire/ --Â West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2016 and provided detailed financial guidance for full-year 2017.Â
Executive Summary
Fourth-quarter 2016 reported net sales of $382.3 million grew 6.3% over the prior-year quarter. At constant currency, organic sales growth was 7.7%. Full-year 2016 reported net sales of $1.509 billion grew 7.8% over the prior year. At constant currency, organic sales growth was 9.1%. Fourth-quarter 2016 reported diluted EPS was $0.52 as compared to $0.45 in the prior-year... More